{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:06:22Z","timestamp":1775570782237,"version":"3.50.1"},"reference-count":26,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2026]]},"DOI":"10.70352\/scrj.cr.25-0669","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:09:05Z","timestamp":1772748545000},"page":"n\/a","source":"Crossref","is-referenced-by-count":1,"title":["A Case of  Epstein-Barr Virus\u2013Associated Transplanted Kidney Post-Transplant Lymphoproliferative Disorder Complicated by Hemophagocytic Lymphohistiocytosis, Six Years after Transplantation"],"prefix":"10.70352","volume":"12","author":[{"given":"Takato","family":"Waseda","sequence":"first","affiliation":[{"name":"Department of Transplantation and Regenerative Medicine, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9666-4730","authenticated-orcid":false,"given":"Naohiro","family":"Aida","sequence":"additional","affiliation":[{"name":"Department of Transplantation and Regenerative Medicine, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taihei","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Transplantation and Regenerative Medicine, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kenmochi","sequence":"additional","affiliation":[{"name":"Department of Transplantation and Regenerative Medicine, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Allen UD, Preiksaitis JK. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33: e13652.","DOI":"10.1111\/ctr.13652"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) L\u2019Huillier AG, Dipchand AI, Ng VL, et al. Posttransplant lymphoproliferative disorder in pediatric patients: survival rates according to primary sites of occurrence and a proposed clinical categorization. Am J Transplant 2019; 19: 2764\u201374.","DOI":"10.1111\/ajt.15358"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Abbas F, El Kossi M, Shaheen IS, et al. Post-transplantation lymphoproliferative disorders: current concepts and future therapeutic approaches. World J Transplant 2020; 10: 29\u201346.","DOI":"10.5500\/wjt.v10.i2.29"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Wang Z, Xu Y, Zhao J, et al. Epstein-Barr virus-associated monomorphic post-transplant lymphoproliferative disorder after pediatric kidney transplantation: a case report. World J Clin Cases 2021; 9: 469\u201375.","DOI":"10.12998\/wjcc.v9.i2.469"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Ali S, Haji N, Pulipati P, et al. Occurrence of post-transplant lymphoproliferative disease in a renal transplant patient. Cureus 2021; 13: e17930.","DOI":"10.7759\/cureus.17930"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Lindsay J, Othman J, Heldman MR, et al. Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes. Curr Opin Infect Dis 2021; 34: 635\u201345.","DOI":"10.1097\/QCO.0000000000000787"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep 2013; 8: 173\u201383.","DOI":"10.1007\/s11899-013-0162-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Opelz G, D\u00f6hler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222\u201330.","DOI":"10.1046\/j.1600-6143.2003.00325.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Quinlan SC, Pfeiffer RM, Morton LM, et al. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011; 86: 206\u20139.","DOI":"10.1002\/ajh.21911"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Blazquez-Navarro A, Dang-Heine C, Wehler P, et al. Risk factors for Epstein-Barr virus reactivation after renal transplantation: results of a large, multi-centre study. Transpl Int 2021; 34: 1680\u20138.","DOI":"10.1111\/tri.13982"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kremers WK, Devarbhavi HC, Wiesner RH, et al. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 2006; 6: 1017\u201324.","DOI":"10.1111\/j.1600-6143.2006.01294.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008; 8: 984\u20139.","DOI":"10.1111\/j.1600-6143.2008.02167.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol 2010; 149: 693\u2013705.","DOI":"10.1111\/j.1365-2141.2010.08160.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol 2010; 149: 675\u201392.","DOI":"10.1111\/j.1365-2141.2010.08161.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Blaes AH, Peterson BA, Bartlett N, et al. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 2005; 104: 1661\u20137.","DOI":"10.1002\/cncr.21391"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6: 569\u201376.","DOI":"10.1111\/j.1600-6143.2005.01211.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Sprangers B, Riella LV, Dierickx D. Posttransplant lymphoproliferative disorder following kidney transplantation: a review. Am J Kidney Dis 2021; 78: 272\u201381.","DOI":"10.1053\/j.ajkd.2021.01.015"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Petrara MR, Giunco S, Serraino D, et al. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment. Cancer Lett 2015; 369: 37\u201344.","DOI":"10.1016\/j.canlet.2015.08.007"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Markouli M, Ullah F, Omar N, et al. Recent advances in adult post-transplant lymphoproliferative disorder. Cancers (Basel) 2022; 14: 5949.","DOI":"10.3390\/cancers14235949"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Gupta D, Mendonca S, Chakraborty S, et al. Post transplant lymphoproliferative disorder. Indian J Hematol Blood Transfus 2020; 36: 229\u201337.","DOI":"10.1007\/s12288-019-01182-x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010; 10: 1517\u201323.","DOI":"10.1111\/j.1600-6143.2010.03156.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Yang Y, Yu B, Chen Y. Blood disorders typically associated with renal transplantation. Front Cell Dev Biol 2015; 3: 18.","DOI":"10.3389\/fcell.2015.00018"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Rouphael NG, Talati NJ, Vaughan C, et al. Infections associated with haemophagocytic syndrome. Lancet Infect Dis 2007; 7: 814\u201322.","DOI":"10.1016\/S1473-3099(07)70290-6"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Kim YR, Kim DY. Current status of the diagnosis and treatment of hemophagocytic lymphohistiocytosis in adults. Blood Res 2021; 56(S1): S17\u201325.","DOI":"10.5045\/br.2021.2020323"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Ponnatt TS, Lilley CM, Mirza KM. Hemophagocytic lymphohistiocytosis. Arch Pathol Lab Med 2022; 146: 507\u201319.","DOI":"10.5858\/arpa.2020-0802-RA"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) San-Juan R, Comoli P, Caillard S, et al. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clin Microbiol Infect 2014; 20 (Suppl 7): 109\u201318.","DOI":"10.1111\/1469-0691.12534"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.25-0669\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T05:01:54Z","timestamp":1772859714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.25-0669\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.25-0669","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"cr.25-0669"}}